[en] Human 16K PRL (16K hPRL) is a potent inhibitor of angiogenesis both in vitro and in vivo. It has been shown to prevent tumor growth in three xenograft mouse models. Here we have used a gene transfer method based on cationic liposomes to produce 16K hPRL and demonstrate that 16K hPRL inhibits tumor growth in a subcutaneous B16F10 mouse melanoma model. Computer-assisted image analysis shows that 16K hPRL treatment results in the reduction of tumor vessel length and width, leading to a 57% reduction in average vessel size. We thus show, for the first time, that administration of the 16K hPRL gene complexed to cationic liposomes is effective to maintain antiangiogenic activities of 16K hPRL level.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Kinet, Virginie ; Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire
Nguyen, Ngoc-Quynh-Nhu ; Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire
Sabatel, Céline ; Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire
Blacher, Silvia ; Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
Noël, Agnès ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme
Martial, Joseph ; Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire
Struman, Ingrid ; Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire
Language :
English
Title :
Antiangiogenic liposomal gene therapy with 16K human prolactin efficiently reduces tumor growth.
Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438 (2005) 932-936
Tandle A., Blazer III D.G., and Libutti S.K. Antiangiogenic gene therapy of cancer: recent developments. J. Trans. Med. 2 (2004) 22
Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3 (2003) 401-410
Folkman J. Endogenous angiogenesis inhibitors. Apmis 112 (2004) 496-507
Ferrara N., Clapp C., and Weiner R. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology 129 (1991) 896-900
D'Angelo G., Struman I., Martial J., and Weiner R.I. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc. Natl. Acad. Sci. USA 92 (1995) 6374-6378
D'Angelo G., Martini J.F., Iiri T., Fantl W.J., Martial J., and Weiner R.I. 16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells. Mol. Endocrinol. 13 (1999) 692-704
Lee H., Struman I., Clapp C., Martial J., and Weiner R.I. Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression. Endocrinology 139 (1998) 3696-3703
Martini J.F., Piot C., Humeau L.M., Struman I., Martial J.A., and Weiner R.I. The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation. Mol. Endocrinol. 14 (2000) 1536-1549
Tabruyn S.P., Sorlet C.M., Rentier-Delrue F., Bours V., Weiner R.I., Martial J.A., and Struman I. The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappa B. Mol. Endocrinol. 17 (2003) 1815-1823
Tabruyn S.P., Sabatel C., Nguyen N.Q., Verhaeghe C., Castermans K., Malvaux L., Griffioen A.W., Martial J.A., and Struman I. The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-kappa B activation. Mol. Endocrinol. 21 (2007) 1422-1429
Clapp C., Martial J.A., Guzman R.C., Rentier-Delure F., and Weiner R.I. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 133 (1993) 1292-1299
Hilfiker-Kleiner D., Kaminski K., Podewski E., Bonda T., Schaefer A., Sliwa K., Forster O., Quint A., Landmesser U., Doerries C., Luchtefeld M., Poli V., Schneider M.D., Balligand J.L., Desjardins F., Ansari A., Struman I., Nguyen N.Q., Zschemisch N.H., Klein G., Heusch G., Schulz R., Hilfiker A., and Drexler H. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128 (2007) 589-600
Bentzien F., Struman I., Martini J.F., Martial J., and Weiner R. Expression of the antiangiogenic factor 16 K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice. Cancer Res. 61 (2001) 7356-7362
Kim J., Luo W., Chen D.T., Earley K., Tunstead J., Yu-Lee L.Y., and Lin S.H. Antitumor activity of the 16-kDa prolactin fragment in prostate cancer. Cancer Res. 63 (2003) 386-393
Nguyen N.Q., Cornet A., Blacher S., Tabruyn S.P., Foidart J.M., Noel A., Martial J.A., and Struman I. Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K hPRL. Mol. Ther. 15 (2007) 2094-2100
Cao Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int. J. Biochem. Cell Biol. 33 (2001) 357-369
Thurston G., McLean J.W., Rizen M., Baluk P., Haskell A., Murphy T.J., Hanahan D., and McDonald D.M. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J. Clin. Invest. 101 (1998) 1401-1413
Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control Release 65 (2000) 271-284
Kim K.S., Kim H.S., Park J.S., Kwon Y.G., and Park Y.S. Inhibition of B16BL6 tumor progression by coadministration of recombinant angiostatin K1-3 and endostatin genes with cationic liposomes. Cancer Gene Ther. 11 (2004) 441-449
Kim S.I., Kim K.S., Kim H.S., Kim D.S., Jang Y., Chung K.H., and Park Y.S. Inhibitory effect of the salmosin gene transferred by cationic liposomes on the progression of B16BL6 tumors. Cancer Res. 63 (2003) 6458-6462
Katanasaka Y., Ida T., Asai T., Maeda N., and Oku N. Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes. Int. J. Pharm. 360 (2008) 219-224
Pan H., Nguyen N.Q., Yoshida H., Bentzien F., Shaw L.C., Rentier-Delrue F., Martial J.A., Weiner R., Struman I., and Grant M.B. Molecular targeting of antiangiogenic factor 16 K hPRL inhibits oxygen-induced retinopathy in mice. Invest. Ophthalmol. Vis. Sci. 45 (2004) 2413-2419
Folkman J. Tumor angiogenesis: therapeutic implications. New Engl. J. Med. 285 (1971) 1182-1186
Bouck N., Stellmach V., and Hsu S.C. How tumors become angiogenic. Adv. Cancer Res. 69 (1996) 135-174
Chen Q.R., Kumar D., Stass S.A., and Mixson A.J. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res. 59 (1999) 3308-3312
Rodolfo M., Cato E.M., Soldati S., Ceruti R., Asioli M., Scanziani E., Vezzoni P., Parmiani G., and Sacco M.G. Growth of human melanoma xenografts is suppressed by systemic angiostatin gene therapy. Cancer Gene Ther. 8 (2001) 491-496
Gonzalez C., Corbacho A.M., Eiserich J.P., Garcia C., Lopez-Barrera F., Morales-Tlalpan V., Barajas-Espinosa A., Diaz-Munoz M., Rubio R., Lin S.H., Martinez de la Escalera G., and Clapp C. 16K-prolactin inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization, and endothelium-dependent vasorelaxation. Endocrinology 145 (2004) 5714-5722
